Compare 10X Genomics Inc (TXG) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard Growth Index Fund ETF — how do they compare? 10X Genomics Inc trades at $79.3 (market cap $9.92B), while Vanguard Growth Index Fund ETF trades at $91.99 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 38.8× 10X Genomics Inc's market cap, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| TXG | VUG | |
|---|---|---|
Market Cap | $9.92B | $384.60B |
Volume | 9,372,166 | 4,760,473 |
Sector | Health | Sector/Thematic |
52-Week High | $97.74 | $92.64 |
52-Week Low | $11.48 | $70.00 |
Typical Hold Time | 92 Days | 47 Days |
Enterprise Value | $9.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
VUG trades at $92.42, down 0.24% with bullish technical signals from moving averages but bearish oscillators suggesting potential overbought conditions. The ETF maintains strong long-term performance with 12% average annual returns since inception, though current RSI levels indicate near-term caution. Recent news highlights VUG's concentration in mega-cap technology stocks like Nvidia, Apple, and Microsoft, which comprise over 36% of holdings.
Long-term growth prospects remain favorable given VUG's historical outperformance and low 0.03% expense ratio. However, significant concentration risk in technology sector and elevated RSI levels present near-term headwinds. The ETF's value proposition centers on cost-efficient exposure to large-cap growth stocks for investors with multi-decade time horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
